Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
June 01, 2022 13:33 ET
|
Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
February 08, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
December 21, 2021 09:39 ET
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
September 21, 2021 09:30 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
September 08, 2021 10:02 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Intrommune Therapeutics Launches #PeanutAllergyStrong
August 24, 2021 12:25 ET
|
Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
August 11, 2021 13:37 ET
|
Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
July 28, 2021 14:10 ET
|
Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...